Intrauterine Devices Market Size, Share, and Industry Analysis, By Product (Devices [By Device Type {Hormonal Intrauterine Device (IUD), and Non-hormonal Intrauterine Device (IUD) [Copper Intrauterine Device (IUD), Silver Intrauterine Device (IUD), and Gold Intrauterine Device (IUD)]}, and By Shape {T-shape, U-shape, Y-shape, and Spherical}], and Accessories), By Distribution Channel (Hospital Pharmacy, Drug Stores & Retail Pharmacy, and Others), and Regional Forecast, 2026-2034

The global intrauterine devices market size was valued at USD 4.48 billion in 2025. The market is projected to grow from USD 5.03 billion in 2026 to USD 12.55 billion by 2034, exhibiting a CAGR of 12.11% during the forecast period.

The global intrauterine devices market is anticipated to witness significant growth during the forecast period. An intrauterine device (IUD) is a type of birth control that a healthcare provider inserts into the uterus. IUDs are the most commonly used type of long-acting reversible contraception (LARC). These devices are of two types, mainly hormonal and non-hormonal IUDs. The increasing market players' focus on receiving approvals from regulatory authorities regarding the extension of usage of intrauterine devices for birth control is one of the important factors driving market growth. 

For example, in June 2024, the Therapeutic Goods Administration (TGA) approved the use of Mirena, a hormonal intra-uterine device (IUD) for up to eight years for contraception, which was previously approved for up to five years of use for contraception.

Moreover, the increasing fertility rate, growing awareness about contraceptive methods, and new product launches are further supplementing the market growth.

Intrauterine Devices Market Driver

The Growing Fertility Rate is Expected to Increase the Demand for Intrauterine Devices (IUDs), thereby Driving Market Growth

The growing fertility rate worldwide is one of the important factors substantially driving the intrauterine devices market growth. As the fertility rate increases, especially in developing countries, there is a higher number of pregnancies, and many of these pregnancies are unplanned. This leads to the greater demand for effective and long-acting contraception methods, such as IUDs.

• For instance, as per the data provided by the Hindu in February 2025, the birth rate per woman in South Korea was 0.72 in 2023, which increased to 0.75 in 2024.

Moreover, in response to rising fertility rates, many government facilities and NGOs are promoting the use of intrauterine devices as a part of national family planning programs. 

The Total Fertility Rate Per Woman in European Countries, 2022-2023

For example, as per the data provided by Eurostat in February 2025, the total fertility rate stood at 1.78 live births per woman in Bulgaria in 2022. This fertility rate was increased to 1.81 per woman in 2023.

Intrauterine Devices Market Restraint

The High Cost of Intrauterine Devices (IUDs) and the Availability of Various Alternatives are Restricting the Market Growth

The high cost of intrauterine devices (IUDs) restricts market growth, especially in the healthcare facilities of low-income countries, as they are expensive for patients in these countries. 

• For example, as per the data provided by Health, before the insertion of intrauterine devices there are several tests need to be performed. These tests include pre-insertion STD testing, which ranges from USD 25.0 to USD 200.0. Additionally, the pregnancy test before insertion can cost upto USD 20.0. Moreover, the cost of intrauterine devices ranges from USD 400 to USD 1,000. Also, the cost of insertion/removal is around USD 125.0 to USD 400.0 
• Furthermore, as per the same source, the out-of-pocket costs based on the type of IUD vary. The cost for copper IUDs (10-year IUDs) is USD 1,000.0 or more. Also, the cost for Levonorgestrel IUD (5-year IUD) ranges from USD 100.0 to USD 1,000.0.

Furthermore, the availability of alternatives such as oral contraceptive pills (combined pill and progestogen-only pill), vaginal rings, and barrier methods (external and internal condoms, diaphragms) is limiting the adoption of IUDs, thereby hindering market growth. 

Intrauterine Devices Market Opportunity

The Increasing Key Players' Focus on Conducting Clinical Trials to Launch Novel Products in the Market, Creating New Opportunities for Market Growth

The increasing focus of key players on conducting clinical trials for the launch of novel intrauterine devices (IUDs) is a significant driver for market growth, creating new opportunities by demonstrating efficacy, safety, and expanding the range of available options. This includes developing hormone-free and longer-lasting IUDs, as well as improving insertion techniques and addressing potential side effects, all of which enhance patient satisfaction and drive adoption.

• For example, in January 2025, Sebela Women's Health Inc., a subsidiary of Sebela Pharmaceuticals, announced the positive results of its phase 3 study of the investigational Copper 175mm2 intrauterine device (IUD). The study result concluded the efficacy, safety, and tolerability of the Copper 175mm2 IUD during the first three years of use.

Moreover, the increasing healthcare organizations' focus on creating awareness about intrauterine devices (IUDs) and their long-term reversible contraceptive effects is creating significant opportunities for market growth. 

Key Insights

The report covers the following key insights:

• Fertility Statistics, by Key Countries, 2024
• Regulatory Scenario, by Key Countries
• New Product Launches, by Key Players
• Key industry developments (Mergers, acquisitions, partnerships, etc.)

Segmentation

Analysis by Product

Based on the product, the market is segmented into devices and accessories. The devices segment is further categorized into hormonal intrauterine device (IUD) and non-hormonal intrauterine device (IUD) based on its type. Moreover, the non-hormonal intrauterine device (IUD) segment is divided into copper intrauterine device (IUD), silver intrauterine device (IUD), and gold intrauterine device (IUD). Furthermore, the devices segment is classified into T-shape, U-shape, Y-shape, and spherical based on their shape. 

The devices segment is anticipated to grow at the highest CAGR from 2025 to 2032. The increasing market players' focus on receiving approvals from regulatory authorities regarding the extension of usage of intrauterine devices for birth control is one of the important factors driving segmental growth during the forecast period. 

• For example, in August 2022, Bayer AG announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) that extends the duration of use for its market-leading intrauterine device (IUD) Mirena (levonorgestrel-releasing intrauterine system) 52 mg by one more year, making it available to prevent pregnancy for up to eight years.

Analysis by Distribution Channel

In terms of distribution channel, the market is divided into hospital pharmacy, drug stores & retail pharmacy, and others. 

The hospital pharmacy segment is projected to dominate the market during the forecast period. Hospital pharmacy is a major source for contraceptive devices, owing to the increasing uptake of implantable contraceptive devices by healthcare professionals and active government support for the distribution of contraceptives through government-aided hospitals across the globe. Moreover, the opening of new hospital pharmacies is positively impacting the intrauterine devices (IUDs) market by increasing accessibility and convenience for women seeking long-acting reversible contraception.

• For example, in May 2025, the Yale New Haven Health Pharmacy was opened at Bridgeport Hospital to provide all pharmacy services.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for the dominant share of the global intrauterine devices market in 2024. The market in this region is expected to grow significantly from 2025 to 2032, owing to increasing market players' focus on receiving regulatory approvals for the launch of intrauterine devices. 

• For example, in February 2025, Sebela Women's Health Inc., a part of Sebela Pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) granted approval of MIUDELLA (copper intrauterine system) for the prevention of pregnancy in females of reproductive potential for up to three years.

The market in Europe is anticipated to grow moderately during the forecast period. The government organizations are actively promoting family planning and reproductive health, leading to increasing awareness and access to IUDs, thereby driving market growth.

• For example, in February 2024, the European Parliamentary Forum for Sexual & Reproductive Rights launched the 7th edition of the EPF Contraception Policy Atlas Europe. This event was organized to create awareness about family planning and reproductive health.

On the other hand, the market in the Asia Pacific region is expected to grow considerably during the forecast period, owing to the increasing launch of intrauterine devices.

Key Players Covered

The global intrauterine devices market consists of companies such as Pregna International Limited, Bayer AG, CooperSurgical, Inc., and Prosan International BV. 

The report includes the profiles of the following key players

• Pregna International Limited (India)
• SMB Corporation of India (India)
• Bayer AG (Germany)
• AbbVie Inc. (U.S.)
• CooperSurgical, Inc. (U.S.)
• DKT INTERNATIONAL (U.S.)
• Mona Lisa N.V. (Belgium)
• OCON Medical Ltd. (Israel)
• Prosan International BV (Netherlands)

Key Industry Developments

• In September 2024, CooperSurgical, Inc. introduced a new single-hand inserter in the global market. This inserter is used for the placement of Paragard, a hormone-free copper intrauterine device (IUD).
• In March 2022, Medicines360, Population Services International (PSI), and Society for Family Health (SFH) announced the launch of Avibela (levonorgestrel-releasing intrauterine system) 52 mg in Nigeria.
• In August 2021, Medicines360, Population Services International (PSI), and Society for Family Health (SFH) announced the launch of Avibela (levonorgestrel-releasing intrauterine system) 52 mg in Kenya.